The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS).
 
William D. Tap
Consulting or Advisory Role - Advaxis; Ariad; EMD Serono; Janssen; Plexxikon
Travel, Accommodations, Expenses - Boehringer Ingelheim
Other Relationship - Morphotek
 
Robin L Jones
Research Funding - Bayer; Eisai; GlaxoSmithKline; ImClone Systems; Johnson & Johnson; Morphotek; Novartis; Threshold Pharmaceuticals
 
Bartosz Chmielowski
Honoraria - Amgen; Merck
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); Genentech (Inst); Lilly (Inst); Merck/Schering Plough (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck
 
Anthony D. Elias
Consulting or Advisory Role - Genentech
Research Funding - Astellas Pharma (Inst); Genentech (Inst); Medivation (Inst)
 
Douglas Adkins
Research Funding - AstraZeneca (Inst); Celgene (Inst); Galera Therapeutics (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Soligenix (Inst); VentiRx (Inst)
 
Brian Andrew Van Tine
Honoraria - Avantis Medical Systems; DFINE; EMD Serono; GlaxoSmithKline; Johnson & Johnson; Lilly; Novartis; ZIOPHARM Oncology
Speakers' Bureau - Caris MPI; DFINE; GlaxoSmithKline
Research Funding - Polaris
Expert Testimony - AB Science
 
Mark Agulnik
Speakers' Bureau - GlaxoSmithKline; Novartis
 
Matthew M. Cooney
No Relationships to Disclose
 
Michael B. Livingston
No Relationships to Disclose
 
Gregory K. Pennock
Speakers' Bureau - Bristol-Myers Squibb; Merck
 
Amy Qin
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Ashwin Shahir
Employment - Lilly
 
Robert L. Ilaria
Employment - Lilly
Leadership - Lilly
Stock and Other Ownership Interests - Lilly
Patents, Royalties, Other Intellectual Property - Lilly
 
Ilaria Conti
Employment - Lilly
 
Jan Cosaert
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Honoraria - Lilly
 
Gary K. Schwartz
Honoraria - AstraZeneca; Boehringer Ingelheim; Novartis
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Novartis
Patents, Royalties, Other Intellectual Property - Patent pending regarding development of PNAs for targeted cancer therapy (new technology)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Novartis